Current Issues in the Management of Endometrial Cancer

Bakkum-Gamez, Jamie N.; Gonzalez-Bosquet, Jesus; Laack, Nadia N.; Mariani, Andrea; Dowdy, Sean C.
January 2008
Mayo Clinic Proceedings;Jan2008, Vol. 83 Issue 1, p97
Academic Journal
Endometrial cancer (EC) remains the most common gynecologic malignancy in the United States. It is expected to become more common as the prevalence of obesity, one of the most common risk factors for EC, increases worldwide. The 2 main histologic subcategories of EC, endometrioid and nonendometrioid EC, show unique molecular aberrations and are responsible for markedly disparate clinical behaviors. The primary treatment of EC is surgery, ie, hysterectomy, removal of the adnexa, and pelvic and para-aortic lymphadenectomy, either via laparotomy or endoscopic techniques. Adjuvant therapy is necessary for patients at high risk of recurrence and consists of vaginal brachytherapy, teletherapy, systemic chemotherapy, or some combination thereof. Multi-institutional trials are in progress in this country and in Europe to better define optimal adjuvant treatment for subsets of patients, as well as the role of surgical staging in reducing both overuse and underuse of radiation therapy. Hormonal therapy is an option for some young women with EC who wish to preserve fertility. This review summarizes the diagnosis and management of EC and discusses current controversies and upcoming investigations pertaining to EC staging and adjuvant treatment.


Related Articles

  • Surveillance Strategies after Curative Treatment of Colorectal Cancer. Pfister, David G.; Benson, Al B.; Somerfield, Mark R. // New England Journal of Medicine;6/3/2004, Vol. 350 Issue 23, p2375 

    Presents an exercise in clinical practice where the authors give a brief patient history to a common clinical problem followed by evidence supporting strategies, a review of formal treatment guidelines and their clinical recommendations. Presentation of a 63-year-old male who underwent a...

  • Adjuvant Radiotherapy for Prostate Cancer. Thompson, Ian M. // AUANews;Jan2007, Vol. 12 Issue 1, p10 

    The article discusses adjuvant radiotherapy in the treatment for patients with prostate cancer. Aside from this, suggested treatments for prostate cancer include delayed therapy until symptomatic disease is present and therapy at prostate specific antigen recurrence. The study by the European...

  • Neoadjuvant Therapy in Patients with Pancreatic Cancer: A Disappointing Therapeutic Approach? Zimmermann, Carolin; Folprecht, Gunnar; Zips, Daniel; Pilarsky, Christian; Saeger, Hans Detlev; Grutzmann, Robert // Cancers;2011, Vol. 3 Issue 2, p2286 

    Pancreatic cancer is a devastating disease. It is the fourth leading cause of cancer-related death in Germany. The incidence in 2003/2004 was 16 cases per 100.000 inhabitants. Of all carcinomas, pancreatic cancer has the highest mortality rate, with one- and five-year survival rates of 25% and...

  • HER2 status may predict responsiveness to adjuvant anthracycline therapy. Burress, Paul; Hurd, Thelma C. // Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p26 

    The article discusses research being done on HER2 status and efficacy of adjuvant anthracyclines in early breast cancer. It references a study by A. Gennari et al published in the "Journal of the National Cancer Institute." The study revealed that although patients benefited from anthracyclines,...

  • Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Gusella, M.; Frigo, A. C.; Bolzonella, C.; Marinelli, R.; Barile, C.; Bononi, A.; Crepaldi, G.; Menon, D.; Stievano, L.; Toso, S.; Pasini, F.; Ferrazzi, E.; Padrini, R. // British Journal of Cancer;5/1/2009, Vol. 100 Issue 10, p1549 

    The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil (5FU)/leucovorin therapy. One hundred and...

  • Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. Cantore, Maurizio; Serio, Giovanni; Pederzoli, Paolo; Mambrini, Andrea; Iacono, Calogero; Pulica, Coriolano; Capelli, Paola; Lombardi, Mirko; Torri, Tito; Pacetti, Paola; Pagani, Mauro; Fiorentini, Giammaria // Cancer Chemotherapy & Pharmacology;Oct2006, Vol. 58 Issue 4, p504 

    Background: The role of adjuvant therapy in pancreatic cancer remains controversial. Gemcitabine given systemically seems to be effective; intra-arterial chemotherapy (IAC) has a deep rationale. Patients and methods: The goal was to evaluate the impact of postoperative IAC followed or not by...

  • Clinician and cancer patient views on patient participation in treatment decision-making: a quantitative and qualitative exploration. Pieterse, A. H.; Baas-Thijssen, M. C. M.; Marijnen, C. A. M.; Stiggelbout, A. M. // British Journal of Cancer;9/16/2008, Vol. 99 Issue 6, p875 

    Patient participation in treatment decision-making is being increasingly advocated, although cancer treatments are often guideline-driven. Trade-offs between benefits and side effects underlying guidelines are made by clinicians. Evidence suggests that clinicians are inaccurate at predicting...

  • LOKAL Ä°LERÄ° MEME KANSERLÄ° OLGULARDA NEOADJUVAN KEMOTERAPÄ° SONRASI HASTALIKSIZ VE GENEL SAÄžKALIMI ETKÄ°LEYEN FAKTÖRLER UZUN DÖNEM SONUÇLARIMIZ. Öztürk, Alper; Bozdoğan, Atilla; Selamoğlu, Derya; Müslümanoğlu, Mahmut; İğci, Abdullah; Özmen, Vahit // Meme Sagligi Dergisi / Journal of Breast Health;2012, Vol. 8 Issue 3, p138 

    Introduction: The rate of locally advanced breast cancer (LABC) is low in countries with organized population based mammographic screening (5-10%), but it is more than 50% in low-middle income countries. Aim of this study is to find factors affecting disease free and overall survival in patients...

  • Adjuvant Therapy for Breast Cancer: We Are Solving the Puzzle, But Pieces Are Still Missing. Pritchard, Kathleen I. // JNCI: Journal of the National Cancer Institute;4/4/2007, Vol. 99 Issue 7, p494 

    The article comments on two trials from the Adjuvant Breast Cancer Trials Collaborative Group which provide important information regarding adjuvant therapy for women with breast cancer although their interpretation is impeded by the lack of estrogen receptor measurements in more than 40% of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics